Exploring Double-Digit Growth Stocks in Healthcare

Summary:

Eli Lilly’s stock has surged over 30% this year, driven by the success of its weight loss drugs, Mounjaro and Zepbound. The pharmaceutical company’s focus on dual GIP/GLP-1 receptor agonists has positioned it strongly in a market projected to reach $100 billion by 2030. However, investors seeking similar growth opportunities may consider Viking Therapeutics and CRISPR Therapeutics, both of which have shown significant potential in their respective fields of weight loss drugs and gene editing. These stocks have already risen in the double-digits recently and could see further gains as they advance their pipelines.

What This Means for You:

• Consider emerging players: Viking Therapeutics, with its promising phase 3 weight loss drug, offers a high-growth opportunity in a booming market.
• Leverage gene editing advancements: CRISPR Therapeutics’ approval of Casgevy for blood disorders marks a milestone, with potential for expansion into other diseases.
• Monitor catalysts: Stay updated on clinical trial results and regulatory updates, as these could significantly impact stock performance.
• Long-term outlook: Both companies are positioned for sustained growth, but investors should be cautious of volatility inherent in biotech stocks.

Original Post:

Investors who picked up shares of Eli Lilly (LLY +0.87%) a few years ago likely are very happy right now. The pharmaceutical company has seen its revenue and stock performance soar thanks to its presence in a booming market — and one that’s positioned for more growth ahead. I’m talking about the weight loss drug market, one forecast to reach nearly $100 billion by the end of the decade.

Lilly’s tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss — but doctors have prescribed either for patients aiming to lose weight. It’s part of a class of drugs known as dual GIP/GLP-1 receptor agonists, which work by stimulating hormonal pathways involved in the digestion process.

Mounjaro and Zepbound have been driving double-digit revenue growth at Lilly, and each has reached blockbuster status. All of this has helped Lilly’s stock climb more than 30% just this year — it’s advanced in the triple-digits over three years. But don’t worry if you missed out on Eli Lilly’s gain, and instead, check out the following two healthcare stocks with big catalysts on the horizon. They’ve both climbed in the double-digits over the past six months, and this could be just the beginning…

Image source: Getty Images.

1. Viking Therapeutics

Viking Therapeutics (VKTX +1.20%), like Lilly, is involved in the field of weight loss drugs, but Viking hasn’t yet commercialized a product. The good news is Viking’s candidates — an oral candidate in phase 2 trials and an injectable in phase 3 — are approaching the finish line, and study results have been strong so far. And since demand in the weight loss drug market is high, there’s plenty of room for a new entrant to carve out share.

Viking’s most advanced candidate — the injectable — in an earlier study showed average weight loss of as much as 14.7% after 13 weeks. And weight loss didn’t plateau, suggesting patients could continue losing weight. Now, catalysts ahead are as follows: Viking aims to complete enrollment in one phase 3 trial by the end of the year and the other phase 3 study in the first quarter of next year. These are studies evaluating treatment over 78 weeks.

Viking also will meet with regulators during the current quarter to discuss the next step for its oral candidate, which met goals in a phase 2 dosing study.

Any of this progress could push shares of Viking higher in the months to come, making now a great time to get in on this biotech player.

2. CRISPR Therapeutics

CRISPR Therapeutics (CRSP +3.34%) works in the exciting field of CRISPR gene editing. This involves “fixing” faulty genes responsible for certain diseases, and the technology does this by cutting DNA at a certain location and relying on natural repair processes. The company won approval for its very first gene editing product, Casgevy for blood disorders, a couple of years ago. This was an important milestone, as it demonstrated that the technique works, suggesting it may be used in other disease areas.

CRISPR Therapeutics gained approval for the use of Casgevy in patients 12 and older and now is studying the potential treatment in phase 3 pediatric studies. The company will present data from those studies at the American Society of Hematology (ASH) annual meeting in early December. And the company also expects to report updates for candidate CTX112 in autoimmune diseases and oncology by the end of the year.

These reports, if positive, could send CRISPR Therapeutics’ shares higher. On top of this, the company’s Casgevy partner, Vertex Pharmaceuticals, says the treatment is on track for more than $100 million in sales this year and “significant growth” next year. This bodes well for the stock’s performance over the long term, too.

So, if you missed out on Eli Lilly, don’t worry: Viking Therapeutics and CRISPR Therapeutics might offer you a new opportunity for big gains over time.

Extra Information:

GLP-1 Stocks: What Investors Need to Know — Explore the potential of GLP-1 receptor agonists in the weight loss drug market.
CRISPR Companies: The Future of Gene Editing — Learn about the transformative potential of CRISPR technology in healthcare.

People Also Ask About:

• What are GIP/GLP-1 receptor agonists? — These are drugs that stimulate hormonal pathways involved in digestion, aiding in weight loss and diabetes management.
• How does CRISPR gene editing work? — It involves cutting DNA at specific locations to repair faulty genes, potentially treating various diseases.
• What is Viking Therapeutics’ most advanced drug? — Their injectable weight loss drug, currently in phase 3 trials, has shown promising results.
• What is Casgevy used for? — It’s a CRISPR-based treatment approved for treating blood disorders like sickle cell disease.
• Are biotech stocks a good long-term investment? — While volatile, they offer high growth potential, especially in emerging fields like gene editing and weight loss drugs.

Expert Opinion:

The rapid advancements in weight loss drugs and gene editing technologies underscore a transformative era in healthcare. Companies like Viking Therapeutics and CRISPR Therapeutics are well-positioned to capitalize on these trends, offering investors opportunities for significant returns. However, the inherent risks of biotech investments necessitate careful due diligence and a long-term perspective.

Key Terms:

• weight loss drug market
• dual GIP/GLP-1 receptor agonists
• CRISPR gene editing technology
• biotech stock investment opportunities
• clinical trial catalysts

Grokipedia Verified Facts

{Grokipedia: Exploring Double-Digit Growth Stocks in Healthcare}

Want the full truth layer?

Grokipedia Deep Search → https://grokipedia.com

Powered by xAI • Real-time fact engine • Built for truth hunters

ORIGINAL SOURCE:

Source link